Myoclonic Epilepsy With Ragged Red Fibers (Merrf) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Myoclonic Epilepsy with Ragged-Red Fibers (MERRF) is a rare multisystem mitochondrial disorder characterized by myoclonus, seizures, ataxia, and ragged-red fiber myopathy. It is caused by mutations in mitochondrial DNA and represents one of the most common mitochondrial encephalomyopathies[1]. The disease typically presents in adolescence or young adulthood but can occur at any age. MERRF is part of a group of disorders known as mitochondrial encephalomyopathies, which also includes MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes) syndrome, with which it shares clinical and genetic overlap[2].
MERRF follows maternal inheritance (mitochondrial inheritance), as it is caused by mutations in mitochondrial DNA (mtDNA). However, phenotype variability is high due to heteroplasmy—the mixture of mutant and normal mitochondria within cells and tissues. This heteroplasmy level varies between individuals and even between different tissues within the same person, which explains the wide spectrum of clinical presentations[3].
MERRF mutations in the mitochondrial tRNALys gene impair mitochondrial protein synthesis, leading to defective oxidative phosphorylation. This results in[5]:
Several clinical trials are investigating novel therapies for mitochondrial diseases including MERRF:
The study of Myoclonic Epilepsy With Ragged Red Fibers (Merrf) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell. 1990;61(6):931-937. DOI:10.1016/0092-8674(9090059-4 ↩︎
Hirano M, Pavlakis SG. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): current concepts. J Child Neurol. 1994;9(1):4-9. DOI:10.1177/088307389400900102 ↩︎
Wallace DC, Lott MT, Shoffner JM, Ballinger S. Mitochondrial DNA mutations in epilepsy and neurological disease. Epilepsia. 1994;35 Suppl 1:S43-50. DOI:10.1111/j.1528-1157.1994.tb05904.x ↩︎
Mancuso M, Orsucci D, Angelini C, et al. Phenotypic heterogeneity of the 8344A>G mtDNA "MERRF" mutation. Neurology. 2013;80(5):2049-2055. DOI:10.1212/WNL.0b013e318276e0be ↩︎
Silvestri G, Mongini T, Tonoli P, et al. Muscle pathology in MERRF: significance of mitochondrial DNA mutations in pathogenesis. J Neurol Sci. 1997;150(1):S148. DOI:10.1016/S0022-510X(9780484-5 ↩︎
Fujita Y, Matsuishi T, Uozumi K, et al. Neuropathological features of the brain in a patient with MERRF. Brain Dev. 1995;17(3):217-220. DOI:10.1016/0387-7604(9500039-4 ↩︎
Finsterer J. MERRF phenotype: a differential diagnosis of Huntington's Disease. J Neurol Sci. 2009;285(1-2):133-138. DOI:10.1016/j.jns.2009.05.016 ↩︎
Tetsuka S, Morita M, Iida K, et al. MERRF presenting with frequent seizures and successful control with L-arginine: a case report. Brain Dev. 2014;36(10):876-880. DOI:10.1016/j.braindev.2014.01.005 ↩︎
Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Neurol. 2013;74(1):130-140. DOI:10.1002/ana.23928 ↩︎
Horvath R, Schneider G, Bhatt SS, et al. Phenotypic spectrum of mitochondrial DNA depletion syndrome. Neurology. 2009;73(24):2060-2065. DOI:10.1212/WNL.0b013e3181e8e040 ↩︎
DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep. 2007;27(1-3):125-137. DOI:10.1007/s10540-007-9041-4 ↩︎
Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF. Brain. 1997;120(Pt 10):1713-1721. DOI:10.1093/brain/120.10.1713 ↩︎